Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
UNAIDS welcomes further evidence that starting antiretroviral therapy early saves lives

“Every person living with HIV should have immediate access to life-saving antiretroviral therapy,” said Michel Sidibé, Executive Director of UNAIDS. “Delaying access to HIV treatment under any pretext is denying the right to health.”

Published
2 hours ago
From
UNAIDS
i-Base Q&A on the START study results

On 27 May 2015, early results showed that the early treatment group did better. One of the surprises is that even at very high CD4 counts, treatment reduces the risk of HIV related illnesses.

Published
2 hours ago
From
HIV i-Base
START trial finds that early treatment improves outcomes for people with HIV

A major international randomised clinical trial has found that people living with HIV have a considerably lower risk of developing AIDS or other serious illnesses

Published
17 hours ago
By
Gus Cairns
High lifetime costs of treating HIV show importance of investing in prevention

The lifetime cost for treating one HIV infection in the UK is almost £380,000, according to a model published in the online journal PLOS One. Switching to generic

Published
19 hours ago
By
Michael Carter
ViiV Healthcare and CHAI collaboration delivers second milestone with first filing with the FDA of generic dolutegravir by Aurobindo Pharma for the treatment of HIV

ViiV Healthcare, Aurobindo Pharma, and the Clinton Health Access Initiative, Inc. (CHAI) announced today that Aurobindo Pharma has submitted an Abbreviated New Drug Application (ANDA) for dolutegravir 50mg, for Tentative Approval, to the Food and Drug Administration (FDA), for the treatment of HIV. This is the first ANDA for a generic version of dolutegravir, less than two years after FDA approval of Tivicay® (dolutegravir) for sale in the United States. Upon receiving Tentative Approval from the FDA, Aurobindo Pharma will be able to supply dolutegravir 50mg via the President’s Emergency Plan for AIDS Relief (PEPFAR) programme, following completion of required local regulatory approval process, in the licensed countries outside of the United States, as per the agreement signed between Aurobindo Pharma and ViiV Healthcare in 2014.

Published
26 May 2015
From
ViiV Healthcare
Maligned Study on Gay Unions Is Shaking Trust

In 2012, as same-sex marriage advocates were working to build support in California, Michael LaCour, a political science researcher at the University of California, Los Angeles, asked a critical question: Can canvassers with a personal stake in an issue — in this case, gay men and women — actually sway voters’ opinions in a lasting way? Last week, their finding that gay canvassers were in fact powerfully persuasive with people who had voted against same-sex marriage — published in December in Science, one of the world’s leading scientific journals — collapsed amid accusations that Mr. LaCour had misrepresented his study methods and lacked the evidence to back up his findings.

Published
26 May 2015
From
New York Times
EMA Panel Recommends Evotaz for Adults With HIV-1

The Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) has recommended granting marketing authorization for atazanavir/cobicistat (Evotaz, Bristol-Myers Squibb Pharma EEIG) for the treatment of adults with HIV-1 infection and no known mutations associated with atazanavir resistance

Published
26 May 2015
From
Medscape
Lower daily tenofovir dose of 150mg safe and effective in people with moderate renal impairment

A reduced tenofovir (Viread) dose of 150mg daily appears to be a safe and effective treatment for people with HIV who have moderate renal impairment, investigators from

Published
22 May 2015
By
Michael Carter
Is Gilead Sciences Its Own Worst Enemy?

Gilead's science is so good that it's actually destroying the company's business. Pharma companies, like most other businesses, make the bulk of their money through repeat business. Gilead, however, is doing something really no other drugmaker is doing -- namely curing patients of devastating infectious diseases.

Published
20 May 2015
From
Motley Fool
HIV immunity: rare gene differences offer hope for treatment

Seven years after the ‘Berlin patient’ was cured of HIV, scientists are looking to natural immunity through genetic variation to create vaccine and gene therapies

Published
12 May 2015
From
The Guardian
← First12345...387Next →

Filter by country